STOCK TITAN

ImmuCell Q3 2026 earnings swing to $953K profit

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

ImmuCell Corporation (ICCC) reported third-quarter 2026 product sales of $8.040 million, up 46.0% from $5.506 million a year earlier. Gross margin was 44.2%, compared with 42.9%; net income was $953,000, versus a $140,000 net loss. Adjusted EBITDA was $1.884 million, compared with $750,000. Management said distributor out-the-door volume grew 18% year over year, and that the sales comparison benefited in part from the absence of distributor restocking headwinds that affected 2025.

At September 30, 2026, cash and cash equivalents were $7.914 million, compared with $3.807 million at December 31, 2025; the increase benefited in part from a $2 million settlement payment received in May 2026. Cash from operating activities was $7.348 million for the first nine months of 2026, compared with $1.993 million in 2025. Management said it negotiated a new, larger $3 million bank line of credit expected to be signed during Q4 2026 and terminated its at-the-market offering, citing its cash position. Capacity expansion and colostrum-sourcing efforts were projected to finish on time and within budget.

4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointThird-quarter product sales reached $8.040 million, up 46.0%.
  • Moderate pointNet income was $953,000, versus a $140,000 year-earlier loss.
  • Moderate pointAdjusted EBITDA was $1.884 million, compared with $750,000 a year earlier.
  • Moderate pointCash from operating activities was $7.348 million, versus $1.993 million.

Negative

  • None.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Product sales $8.040 million Third quarter 2026; up 46.0% from $5.506 million in the third quarter of 2025
Gross margin 44.2% Third quarter 2026; compared with 42.9% in the third quarter of 2025
Net income $953,000 Third quarter 2026; compared with a $140,000 net loss in the third quarter of 2025
Adjusted EBITDA $1.884 million Third quarter 2026; compared with $750,000 in the third quarter of 2025
Cash and cash equivalents $7.914 million As of September 30, 2026; compared with $3.807 million as of December 31, 2025
Cash from operating activities $7.348 million Nine months ended September 30, 2026; compared with $1.993 million in 2025
Line of credit $3 million Management said it was negotiated and expected to be signed during Q4 2026
Distributor out-the-door volume growth 18% Growth over 2025
Adjusted EBITDA financial
"Adjusted EBITDA was $1.9 million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
At-The-Market offering financial
"terminated our At-The-Market offering"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
gross margin financial
"Gross margin was 44.2%"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
net working capital financial
"Net working capital increased to approximately $16.9 million"
Net working capital is the amount left when you subtract a company’s short-term bills (like accounts payable and short-term loans) from its short-term assets (cash, money owed to it, and inventory). Think of it as the cash cushion a business has to keep daily operations running — a bigger cushion means fewer short-term funding worries, while a small or negative number can signal pressure to raise cash or cut activity, which matters to investors assessing stability and short-term risk.
colostrum-derived antibodies medical
"colostrum-derived, orally delivered antibodies"
out-the-door volume financial
"distributor out-the-door volume growth of 18%"
Product sales $8.040 million Up 46.0% from $5.506 million in the third quarter of 2025
Gross margin 44.2% Up 130 basis points from 42.9% in the third quarter of 2025
Net income $953,000 Compared with a $140,000 net loss in the third quarter of 2025
Adjusted EBITDA $1.884 million Compared with $750,000 in the third quarter of 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did ICCC report in the third quarter of 2026?

ImmuCell reported product sales of $8.040 million for the quarter ended September 30, 2026, up 46.0% from $5.506 million a year earlier. Management said the comparison benefited in part from the absence of distributor restocking headwinds that affected third-quarter 2025 sales.

What were ICCC’s third-quarter 2026 net income and adjusted EBITDA?

ImmuCell reported net income of $953,000 for the quarter ended September 30, 2026, compared with a $140,000 net loss a year earlier. Adjusted EBITDA was $1.884 million, compared with $750,000 in the third quarter of 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000811641 0000811641 2026-11-12 2026-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 12, 2026
 
 
ImmuCell Corporation
(Exact name of registrant as specified in its charter)
 
 
DE
 
001-12934
 
01-0382980
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
56 Evergreen Drive Portland, Maine
 
04103
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code 207-878-2770
 
 
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.10 par value per share
 
ICCC
 
The NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

 
ITEM 2.02. Results of Operations and Financial Condition
 
On November 12, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. 
 

 
Item 9.01.  Exhibits.
 
(d)           Exhibits.
 
 
 
99.1
Press Release of the Company dated November 12, 2026
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 

 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
IMMUCELL CORPORATION
 
 
Date: November 12, 2026
By:
/s/ Timothy C. Fiori
 
 
Timothy C. Fiori
 
 
Chief Financial Officer
 

 
Exhibit Index
 
 
Exhibit No.
Description
99.1
99.1 Press Release of the Company dated November 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

Exhibit 99.1

ImmuCell


 

 

 

                  

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026

 

For Immediate Release

 

PORTLAND, Maine – October 12, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the third quarter of 2026.

 

Management’s Discussion: 

“Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025. Gross margin was 44.2% in the third quarter of 2026, which is 130 basis points higher than the third quarter of 2025 and reflects higher pricing and manufacturing execution partially offset by the previously discussed shift of certain product development expenses to costs of goods sold.” 

 

“We are pleased with our third quarter revenue and with distributor out-the-door volume growth of 18% over 2025,” commented Bobbi Jo Brockmann, Senior Vice President of Sales & Marketing. “Growth remained broad-based across our sales territories and product lines, supported by an increase in sales activity and continued progress in customer acquisition. We are also encouraged by inventory levels heading into our peak season as we shift our focus to the cow-calf market.”

 

“ImmuCell had a strong quarter. The expanded commercial team is delivering solid revenue growth as we reach more customers with our value propositions,” said Olivier te Boekhorst, President and CEO. “Increased commercial activity was supported by increased output from the manufacturing team. We are investing in capacity expansion and colostrum sourcing capabilities for future demand, and those efforts are projected to be completed on time and within budget.”

 

“We have negotiated a new, larger $3 million line of credit with our bank, which we expect to sign during the fourth quarter of 2026,” continued Mr. Fiori. “Additionally, given our strong cash position, we have terminated our At-The-Market offering.”

 

Certain Financial Results:

• Third quarter 2026 product sales increased 46.0%, to approximately $8.0 million, compared to the quarter ended September 30, 2025.

• Third quarter 2026 gross margin increased to 44.2% of product sales compared to 42.9% during the quarter ended September 30, 2025.

• Net income was $953,000, or $0.10 per diluted share, during the quarter ended September 30, 2026, compared to a net loss of $140,000, or ($0.02) per basic share, during the quarter ended September 30, 2025.

• Adjusted EBITDA (calculation methodology shown below) was $1.9 million in the three months ended September 30, 2026, as compared to $0.8 million in the three months ended September 30, 2025.  

 

Balance Sheet Data as of September 30, 2026:

• Cash and cash equivalents increased to $7.9 million as of September 30, 2026, from $3.8 million as of December 31, 2025, such increase benefiting in part from the $2 million settlement payment received in May 2026.  

• Net working capital increased to approximately $16.9 million as of September 30, 2026 from $13.0 million as of December 31, 2025.

• Stockholders’ equity increased to $32.8 million as of September 30, 2026 from $27.1 million as of December 31, 2025.

 


 

Condensed Statements of Income (Unaudited)

 

 

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands, except per share amounts)

2026

2025

2026

2025

 

 

 

 

 

Product sales

$8,040

$5,506

$25,584

$20.018

Costs of goods sold

4,485

3,143

14,934

11,483

Gross profit

3,555

2,363

10,650

8,535

 

 

 

 

 

Sales, marketing and administrative expenses

2,420

1,649

7,174

4,545

Product development expenses

177

694

614

2,283

Other operating income

-

-

(2,000)

-

Operating expenses

2,597

2,343

5,788

6,828

 

 

 

 

 

NET OPERATING INCOME

958

20

4,862

1,707

 

 

 

 

 

Other (expenses) income, net

(22)

(155)

(92)

110

 

 

 

 

 

INCOME (LOSS) BEFORE INCOME TAXES

936

(135)

4,770

1,817

 

 

 

 

 

Income tax (benefit) expense

(17)

5

41

8

 

 

 

 

 

NET INCOME (LOSS)

$953

($140)

$4,729

$1,809

 

 

 

Basic weighted average common shares outstanding

9,084

9,046

9,065

9,019

Basic net income (loss) per share

$0.10

($0.02)

$0.52

$0.20

Diluted weighted average common shares outstanding

9,298

9,046

9,189

9,019

Diluted net income (loss) per share

$0.10

($0.02)

$0.51

$0.20

 

Selected Balance Sheet Data (In thousands) (Unaudited)

 

 

As of September 30, 2026

As of December 31, 2025

Cash and cash equivalents

$7,914

$3,807

Inventory

$9,857

$9,267

Net working capital

$16,897

$12,967

Total assets

$47,958

$42,532

Stockholders' equity

$32,774

$27,055

 

Selected Cash Flow Data (In thousands) (Unaudited)

 

 

Nine Months Ended September 30,

 

2026

2025

Operating Activities

$7,348

$1,993

Investing Activities

(2,247)

(1,047)

Financing Activities

(994)

(818)

Net Change in Cash

4,107

128

Cash at Beginning of Period

3,807

3,758

Cash at End of Period

$7,914

$3,886

 


 

Non-GAAP Financial Measures: Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flow that either excludes or includes amounts that are not normally included in or excluded from the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP measures included in this press release should be considered in addition to, and not as a substitute for or superior to, the comparable measure prepared in accordance with GAAP. 

 

We believe that considering the non-GAAP measure of Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) assists management and investors by looking at our performance across reporting periods on a consistent basis excluding certain charges from our reported income before income taxes. We calculate adjusted EBITDA as described in the following table and reconciled to the most comparable GAAP financial measure:

 

 

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2026

2025

2026

2025

 

 

 

 

 

Net income (Loss)

$953

($140)

$4,729

$1,809

Income tax (benefit) expense

(17)

4

41

8

Interest expense (excluding debt issuance and debt discount costs)

89

105

278

336

Depreciation

459

674

1,458

2,009

Amortization (including debt issuance and debt discount costs)

3

34

9

66

Stock-based compensation expense

397

73

774

192

 

 

 

 

 

Adjusted EBITDA

$1,884

$750

$7,289

$4,420

 

Cash payments to satisfy debt repayment obligations and to make capital expenditure investments are other uses of cash that are not included in the calculation of EBITDA, but which management also does consider when assessing its cash flows.

 

Webcast / Conference Call:

The Company is planning to host a conference call and webcast on November 13, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international).   

 

The live webcast can be accessed at: https://app.webinar.net/JL8AEda3K5D

 

The live webcast will feature a set of accompanying presentation slides that will subsequently be available in the Investors section of the Company’s website at: https://immucell.com/investors/ 

 

A teleconference replay of the conference call will be available through November 20, 2026, by dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access code #2589057.

 


 

About ImmuCell: 

 

ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors.

 

Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):

 

This Press Release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to:

 

• our business plans, goals and strategies;

• projections of future financial and operational performance, expense ratios and margins;

• future demand for our products, including the First Defense® product line;

• the sequence, duration, costs and goals of our program to repurpose our former Re-Tain® facility and equipment for First Defense® production; cost recoveries on Re-Tain® equipment no longer in service; and other elements of projected depreciation expense affecting future income for book and tax return purposes; 

• capital expenditures, contractual commitments, and the anticipated sources and uses of cash to fund them;

• anticipated timing and terms of a new line of credit;

 

and any other statements that are not historical facts. projections about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not historical facts. These statements reflect management’s current expectations as of the date hereof, are based on management’s estimates, projections, beliefs and assumptions as of such date; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to differ materially, including risks relating to: competition in our markets; customer acceptance and product performance; alignment between our manufacturing resources and product demand; supply chain disruptions affecting our operations and our customer and supplier relationships; the commercial and operational risks of our current and planned expansion of production capacity; difficulties or delays in development, testing, regulatory approval, production and marketing of our products, and other risks and uncertainties detailed from time to time in our filings with the Securities and Exchange Commission (SEC), including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. There can be no assurance that the risks or developments we anticipate will be those that actually affect us. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise.

 

Contacts:

Olivier te Boekhorst, President and CEO
Timothy C. Fiori, Chief Financial Officer
ImmuCell Corporation
investor.relations@immucell.com
 

 

Joe Diaz, Robert Blum and Joe Dorame
               Lytham Partners, LLC
               iccc@lythampartners.com

Filing Exhibits & Attachments

5 documents

Keep reading